The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 48 kDa. The detection limit for recombinant Human TRAILReceptor 2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Use a concentration of 0.25 - 1 µg/ml. Use 100 µl/well of antibody solution. ab116663 allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human sTRAIL Receptor 2.
Use a concentration of 0.25 - 1 µg/ml. Use 100 µl/well of antibody solution. ab116663, in conjunction with an sTRAIL Receptor 2 capture antibody allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human sTRAIL Receptor 2
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain.
Squamous cell carcinoma of the head and neck
Contains 1 death domain. Contains 3 TNFR-Cys repeats.